Abstract
Experience of scintigraphic detection of bone lesion and active bone marrow involvement of multiple myeloma, especially with sestamibi and FDG- PET scans is in evolution. We report a case of intense sestamibi uptake in bone marrow correlating with the extent of the disease, while FDG-PET scans showed activity only in areas of active disease progression associated with pain. Technetium-99m-sestamibi appears to indicate the extent of the disease, while [18F]FDG-PET scans show sites of active tumor proliferation and may be useful in directing local therapy such as radiation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1208-1210 |
| Number of pages | 3 |
| Journal | Journal of Nuclear Medicine |
| Volume | 38 |
| Issue number | 8 |
| State | Published - 1997 |
| Externally published | Yes |
Keywords
- Fluorine-18-FDG
- Multiple myeloma
- PET
- Sestamibi
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Fingerprint
Dive into the research topics of 'Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS